In this study the investigators will investigate the acute effects of increasing glucagon exposure on metabolic parameters in healthy participants.
Participants will participate in one study day. After initial baseline blood samples, a three-hour intravenous infusion with glucagon will be initiated. The infusion rate will be increased every 30 minutes.

开始日期2025-04-01

申办/合作机构

University of Copenhagen

NCT06424106

/ RecruitingN/AIIT

Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes

Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.

开始日期2025-04-01

申办/合作机构

Mayo Clinic

NCT06877208

/ Not yet recruitingN/A

The Effect of Glucagon on Cerebral Glucose Metabolism in Healthy Humans

This is a pilot study in which the investigators will investigate the effect of exogenous glucagon on cerebral glucose metabolism in healthy humans.
Participants will participate in either part C or part D of the study, and each participant will participate in three study days. During a study day the participant will receive an intravenous infusion of either glucagon, glucose (in an adjustable rate to match to glucose concentrations achieved with the glucagon infusion) or saline. During each study day an 18F-flouro-deoxy-glucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT) scan will be performed to quantify cerebral glucose metabolism during the first part (acute effect) of the glucagon/glucose/saline infusion (part C) or the last part (later effect) of the glucagon/glucose/saline infusion (part D).

开始日期2025-03-01

申办/合作机构

University of Copenhagen

100 项与胰高血糖素相关的临床结果

登录后查看更多信息

100 项与胰高血糖素相关的转化医学

登录后查看更多信息

100 项与胰高血糖素相关的专利（医药）

登录后查看更多信息

8,639

项与胰高血糖素相关的文献（医药）

2025-05-01·BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

LYPLAL1 enzyme activity is linked to hepatic glucose metabolism

Article

作者: Lefebvre, David ; Chen, Xinhzu ; Bélanger, Étienne ; Filip, Roxana ; Pezacki, John Paul ; Uguccioni, Spencer M

The serine hydrolase LYPLAL1 is a poorly characterised enzyme with emerging roles in hepatic metabolism. A multitude of association studies have shown links between variants of this gene locus and metabolic conditions such as obesity and insulin resistance. However, the enzyme's function is still largely unknown. Recent biochemical studies have revealed that it may play a role in hepatic glucose metabolism and that its activity is allosterically regulated. Herein, we use a selective activity-based probe to delineate LYPLAL1's involvement in hepatic metabolism. We show that the enzyme's activity is modulated during metabolic stress, specifically pointing to a putative role in negatively regulating gluconeogenesis and upregulating glycolysis. We also determine that knock-out of the enzyme does not affect liver lipid profiles and bring forth evidence for insulin-mediated control of LYPLAL1 in HepG2 cells. Furthermore, LYPLAL1 activity appears to be largely post-translationally regulated as gene expression levels remain largely constant under insulin and glucagon treatments. Taken together these data point to an enzymatic role in regulating glucose metabolism that may be part of a feedback mechanism of signal transduction.

2025-04-01·DIABETIC MEDICINE

Exploring low‐dose glucagon for exercise‐induced hypoglycaemia in type 1 diabetes: A randomised controlled trial

Article

作者: Ranjan, Ajenthen Gayathri ; Lundemose, Sissel Banner ; Laugesen, Christian ; Nørgaard, Kirsten

Abstract:

Aims:

This study was designed to compare the effectiveness of a single subcutaneous (s.c.) glucagon dose versus the same total dose split into a dose before and after and placebo (PBO) in preventing exercise‐induced hypoglycaemia in adults with type 1 diabetes (T1D).

Methods:

Twenty‐two adults with T1D participated in a randomised, single‐blinded, three‐arm crossover study. Participants underwent a 60‐min bout of moderate‐intensity cycle ergometry (~50% HRmax) in fasted state, followed by 2 h of rest. Plasma glucose (PG) concentrations were monitored at 5‐ and 15‐minute intervals. Participants were randomly assigned to receive two separate injections before (t = 0 min) and just after (t = 60 min) exercise: (i) 150 μg s.c. glucagon (G150) before and PBO after; (ii) 75 μg s.c. glucagon (G75*2) before and after; or (iii) PBO before and after. Insulin pump users reduced their basal insulin rate by 50% during cycling.

Results:

The occurrence of hypoglycaemia did not significantly differ between arms (G150: 7, G75*2: 5 and PBO: 6 events, p = 0.078). Mean PG levels throughout the trial were lower in the PBO arm compared to both glucagon arms (G150: 8.6 ± 2.9, G75*2: 8.9 ± 3.4 and PBO: 7.3 ± 2.6 mmol/L, p = 0.015). Time spent with PG in target range (3.9–10.0 mmol/L) was higher in the PBO arm versus both glucagon arms (G150: 63.9 ± 38.9%, G75*2: 60.0 ± 34.1% and PBO: 82.7 ± 29.6%, p = 0.005), driven by less time above range (G150: 32.9 ± 41.3%, G75*2: 35.9 ± 36.4% and PBO: 13.2 ± 30.2%, p = 0.007).

Conclusions:

Low‐dose native glucagon did not offer any advantages in preventing exercise‐induced hypoglycaemia in individuals with T1D, regardless of glucagon dosing variations.

2025-04-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Molecular characterization of AMP-activated protein kinase (AMPK) α1/α2 from Cyprinus carpio and its roles in glucolipid metabolism and immune response

Article

作者: Yan, Xiao ; Zhao, Mengjuan ; Qin, Chaobin ; Zhi, Shaoyang ; Yang, Liping ; Li, Yijie ; Wang, Junli ; Wang, Yiran ; Nie, Guoxing

AMPKα1 and AMPKα2, key kinases in regulating energy homeostasis, have not been previously cloned or characterized in common carp (Cyprinus carpio). This study identified the open reading frame (ORF) sequences of ampkα1 (1722 bp, encoding 573 amino acids) and ampkα2 (1659 bp, encoding 552 amino acids) through homologous cloning. Sequence alignment and phylogenetic analysis showed a high similarity of both genes with fish homologs. Expression analysis revealed that ampkα1 and ampkα2 are widely expressed across tissues in carp, with ampkα1 highly expressed in the gonads and ampkα2 in the heart. Fasting significantly reduced ampkα1 expression in the heart, adipose tissue, and foregut but increased it in the hindgut and white muscle. Similarly, ampkα2 expression decreased in the hypothalamus and muscle during fasting, with an increase in the midgut. Glucose tolerance tests showed dynamic regulation of ampkα1 and ampkα2, with initial downregulation followed by upregulation in the hepatopancreas, red muscle, and brain. High-glucose and high-fat diets significantly increased ampkα1 and ampkα2 expression in multiple tissues. Insulin and glucagon treatment induced time-dependent changes in both genes in hepatocytes, while Aeromonas hydrophila infection, LPS, and Poly (I:C) stimulation upregulated ampkα1 and ampkα2 in immune-related tissues. Knockdown of ampkα2, but not ampkα1, reduced glut1b mRNA levels, while both knockdowns of ampkα1 and ampkα2 promoted the expression of gsk3β, pygm, acc, fas, srebp, cs, and pro-inflammatory cytokines, suggesting their involvement in metabolic and immune regulation in carp.

179

项与胰高血糖素相关的新闻（医药）

2025-04-15

·华东医药股份有限公司

英文版 | 创新研发进展不断！华东医药将携十大创新药项目亮相国际大会

Guided by its corporate philosophy of Scientific Research-based and Patient-centered', Huadong Medicine has dedicated itself to advancing treatments in cancer, autoimmune disorders, and chronic metabolic diseases." By continuously increasing R&D investment and actively promoting the progress of clinical trials, we have achieved several significant milestones. In particular, ten of our proprietary research results are scheduled for presentation at major global conferences in the first half of 2025, including the annual meetings of American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), American Diabetes Association (ADA) and European Association for the Study of the Liver (EASL). These presentations will highlight our pioneering contributions to global healthcare innovation.012025AACRThe 2025 Annual Meeting of the American Association for Cancer Research (AACR) will be held from 25 to 30 April in Chicago, USA. As the world's oldest and largest cancer research conference, the AACR will bring together leading scientists, pharmaceutical innovators, and research institutions to highlight high-impact cancer studies and cutting-edge therapeutic advances, showcasing the latest breakthroughs in oncology. At this premier event, Huadong Medicine will make a groundbreaking debut with five novel proprietary therapies selected for poster presentations, including HDM2022: A first-in-class GSPT1 molecular glue degrader with potent anti-tumour activity；HDM2006: The first oral HPK1-targeting PROTAC (proteolysis-targeting chimera) for hematopoietic progenitor kinase inhibition；Three next-generation ADCs, HDM2012: Targeting MUC17 for gastrointestinal cancers, HDM2017: Targeting CDH17 for metastatic solid tumours, HDM2020: An FGFR2b-specific ADC designed for precision therapy in resistant malignancies. These innovations underscore Huadong Medicine's achievements in pioneering transformative oncology solutions.2025H1: Posters at AACRApril 27th2:00PM-5:00PMPoster Section:10 Board Number:13Preclinical development of HDM2020, a novel ADC targeting FGFR2b, in gastric cancer (GC) and squamous non-small cell lung cancer (sq-NSCLC) xenograft modelsAbstract No. 245 Poster Section:15 Board Number:8Translational studies of HDM2012, a novel topoisomerase inhibitor ADC targeting MUC17, in patient derived GC, CRC, PDAC tumor models Abstract No. 316 Poster Section:15 Board Number:9Discovery of HDM2017, a CDH17-targeting ADC for colorectal cancersAbstract No. 317 Poster Section:18 Board Number:383Discovery of potent, selective, and orally bioavailable GSPT1 molecular glue degraders (MGDs) for the treatment of MYC-driven tumors Abstract No. 2161April 29th2:00PM-5:00PM Poster Section:21 Board Number:10HDM2006, A Novel and Potent HPK1 PROTAC, Enhances Immune Cell Activation and Induces Robust Tumor Growth InhibitionAbstract No. 5632022025ASCOThe American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from 30 May to 3 June 2025, is the world's leading professional scientific organization in oncology and is one of the largest and most prestigious global oncology conferences. It serves as a premier platform for the presentation of cutting-edge research and clinical trial data in cancer care.Huadong Medicine will be showcasing its proprietary anti-tumour drug HDM2025 through a poster presentation at this prestigious event. This innovative therapeutic agent demonstrates potent and selective pan-KRAS targeting capabilities, marking a significant advancement in the development of oncology therapeutics.2025H1: Poster at ASCOJune 2nd1:30PM-4:30PMPoster Section:15 Board Number:428Discovery of Potent Degraders of pan-KRAS Based on a Novel KRAS Binder032025ADAThe 85th American Diabetes Association (ADA) Scientific Sessions, a major international academic event in the field of diabetes, will take place in Chicago, USA, from June 20-23, 2025. This esteemed congregation will bring together clinicians, researchers, educators and industry leaders to advance discussions on diabetes-related basic research, clinical practice, prevention strategies and technological innovation. At this landmark conference, Huadong Medicine will present groundbreaking achievements: The company's self-developed GLP-1/GIP dual-target long-acting agonist, HDM1005 Injection, has been selected for an Oral Presentation, emphasizing its innovative therapeutic potential. The poster presentations will feature the company's proprietary research on HDM1002-102, an oral small-molecule GLP-1 agonist, along with Phase III clinical trial results of Semaglutide Injection, highlighting Huadong Medicine' leadership in advancing diabetes care.2025H1: Oral Presentation&Posters at ADAJune 20th5:45PM-6:00PMAbstract Number：142-ORSafety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HDM1005)—A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation StudyJune 22nd12:30PM-1:30PMAbstract Number：737-PHDM1002 in Chinese Adults with Overweight or Obesity-A Randomized, Placebo-Controlled, Four-Week, Phase 1b StudyAbstract Number：839-PEfficacy and Safety of HDG1901 vs Ozempic® in Patients with Type 2 Diabetes (T2D): A Randomized, Open-label, Bioequivalence Phase 3 Trial042025EASLConcurrently, Huadong Medicine' subsidiary Doer Biologics will present groundbreaking clinical research data at the European Association for the Study of the Liver (EASL) Annual Congress 2025, a leading international event in hepatology, taking place in Amsterdam, the Netherlands, from 7 to 10 May. The company will be showing data from its New Zealand-based multi-ascending dose (MAD) study of DR10624-101, an Fc fusion protein drug developed using its proprietary MultipleBody® platform technology, in a poster presentation. DR10624 is the "first-in-class" and the world's first tri-target agonist activating three critical receptors: the glucagon-like peptide-1 receptor (GLP-1R), glucagon receptor (GCGR), and FGFR1c/Klothoβ (FGF21R). This positions it as a pioneering advancement in the field of metabolic and liver disease therapeutics. 2025H1: Posters at EASLMay 7th8:30AM-4:00PMAbstract identifier: LBP-003/FRI-365Late breakerDR10624, a first-in-class, FGF21 receptor (FGF21R)/glucagon receptor (GCGR)/GLP-1 receptor (GLP-1R) triple agonist rapidly and significantly reduced liver fat in obese subjects with modest hypertriglyceridemia: a 12-week randomized, placebo-controlled, double-blind, multi-center trialMay 9th8:30AM-5:00PMDR10624, a novel FGF21R, GCGR, and GLP-1R tri-agonist, demonstrated extraordinary efficacy in B6-Alms1-del mice, a spontaneous MASH model of mice with obesity, hyperglycemia, and dyslipidemia phenotypeHuadong Medicine's participation in a series of leading international academic conferences to highlight its proprietary innovations underscores the growing global recognition of its pioneering R&D capabilities. In the future, Huadong Medicine will continue to commit to its core philosophy of 'Scientific Research-based and Patient-centered' by pursuing proprietary research and strategic collaborations to expand innovative product pipeline,aim to become a powerful international pharmaceutical enterprise driven by scientific research innovation.Statements1.This news article is intended to share frontline updates on the R&D progress of the company (or its partners) and is not for advertising purposes. The information provided is not directed at patients and is for reference by healthcare professionals only.2.This press release does not endorse or recommend any specific pharmaceutical product and/or indication.3.The information contained herein is for reference only and shall be subject to the documents officially released by the company on the Shenzhen Stock Exchange. Neither this press release nor company announcements shall replace professional medical guidance or be construed as diagnostic or treatment advice. For specific disease-related information, please consult physicians or other qualified healthcare professionals.4.As of the date of this release, HDM1002, HDM1005, HDM2006, HDM2012, HDM2017, HDM2020, HDM2022, HDM2025, DR10624, and HDG1901 (the company’s semaglutide injection) have not been approved for marketing by the National Medical Products Administration (NMPA).5.This press release may contain forward-looking statements. Such statements inherently involve risks and uncertainties. Terms such as “anticipate,” “believe,” “predict,” “expect,” “intend,” and similar expressions, when related to the Company, constitute forward-looking statements. The Company is under no obligation to continuously update these predictive statements.These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts, and understandings of the Company’s management regarding future events at the time of publication. They are not guarantees of future performance and are subject to risks, uncertainties, and other factors beyond the Company’s control. Actual results may differ materially from those expressed or implied due to changes in the Company’s business, competitive landscape, and political, economic, legal, and social conditions.The Company, its directors, employees, and agents shall not be liable for (a) any obligation to correct or update forward-looking statements contained herein; or (b) any consequences arising from the failure of such forward-looking statements to materialize or their inaccuracy.v

抗体药物偶联物ASCO会议AACR会议

2025-04-13

·医学新视点

糖尿病患者心肾风险降低多达58%！三联疗法或为临床治疗新选择

▎药明康德内容团队编辑胰高血糖素样肽-1受体激动剂（GLP-1RA）已被证实具有很大治疗潜力，包括降糖、减重，以及降低重大心血管不良事件风险和改善糖尿病患者肾脏预后。近期研究证据显示，GLP-1RA或有益于改善射血分数保留型心力衰竭（HFpEF）的患者的肾脏结局。部分大型临床试验亚组分析结果表明，GLP-1RA和钠-葡萄糖共转运蛋白2抑制剂（SGLT-2i）联合治疗，可减少糖尿病患者心力衰竭住院和肾脏疾病复合事件发生率。在此基础上加用非甾体盐皮质激素受体拮抗剂（MRA）非奈利酮，可能进一步强化心肾保护作用，相关研究结果显示，三联治疗预估可将心血管不良事件风险和慢性肾病进展风险分别降低35%和58%。但GLP-1RA+SGLT-2i+非奈利酮三联疗法的临床效益及适用人群仍需更多研究验证。GLP-1RA可降低糖尿病患者主要不良心血管事件发生风险和肾脏不良结局风险糖尿病是心血管疾病和慢性肾病最重要的危险因素之一。相比于无糖尿病患者，糖尿病患者罹患动脉粥样硬化性心血管疾病的风险高出2~4倍。慢性肾病是糖尿病的主要微血管并发症，会增加心血管疾病和死亡的风险。控制血糖水平有助于预防慢性肾病微血管并发症和心血管事件的发生。对于糖尿病合并心血管疾病或存在多种心血管和肾脏风险的患者，GLP-1RA是治疗可选择用药之一。LEADER试验纳入了2型糖尿病合并心血管高风险的患者9340例，研究人员将患者随机分配接受利拉鲁肽或安慰剂治疗。研究结果显示，平均随访3.8年，相比于安慰剂组，利拉鲁肽组患者的主要不良心血管事件（心血管死亡、非致死性心肌梗死或非致死性卒中的复合终点）减少了13%（HR=0.87）。SUSTAIN-6试验则显示，在2型糖尿病合并心血管高风险患者中，相比于安慰剂组，司美格鲁肽组（皮下注射，每周0.5 mg或1 mg）心血管不良事件风险降低26%（HR=0.74），卒中风险降低了26%。后续Harmony Outcomes、REWIND、AMPLITUDE-O等研究也证实了GLP-1RA在降低2型糖尿病合并心血管高风险患者心血管不良事件、心肌梗死和卒中风险方面的作用。GLP-1RA不仅具有降糖的作用，也具有减重效应。SELECT试验在肥胖[体重指数（BMI）≥27 kg/m2]合并心血管疾病但无糖尿病的患者中开展，探索使用GLP-1RA对于预防心血管事件发生的作用。研究结果显示，在平均3.3年的观察期内，相比于安慰剂，皮下注射司美格鲁肽可使患者体重较基线降低9.39%、心血管不良事件风险降低20%（HR=0.80），尤其是心肌梗死风险降低28%（HR=0.72）。该研究结果提示，GLP-1RA心血管保护作用与减重相关，而非降糖作用。荟萃分析结果表明，GLP-1RA可将糖尿病合并心血管高风险患者的心力衰竭住院率降低约10%。但关于GLP-1RA降低心力衰竭住院风险的研究结果并不完全一致。FIGHT试验纳入因急性心力衰竭住院的射血分数降低的心力衰竭患者300例。所有患者中位左心室射血分数为25%；82%患有缺血性心脏病、59%患有2型糖尿病。结果显示，利拉鲁肽组与安慰剂组死亡（HR=1.10）和心力衰竭再住院（HR=1.30）风险无显著差异，不同糖尿病状态亚组分析结果也相似。因此，关于射血分数降低的心力衰竭患者能否从GLP-1RA用药中获益，仍有待更多证据进行验证。GLP-1RA改善肾脏结局获益的证据多来源于次要结局或探索性分析，其机制可能与大量蛋白尿进展抑制有关，但对其他临床重要肾脏终点的影响尚不明确，包括肾小球滤过率（eGFR）下降速度、开始肾脏替代治疗的时间等。FLOW试验评估皮下注射司美格鲁肽对2型糖尿病患者慢性肾病影响，研究纳入患者3533例，随机接受司美格鲁肽或安慰剂治疗。主要结局为首次肾功能衰竭的时间（持续eGFR<15 ml/min/1.73m2或开始慢性肾脏替代治疗）。研究结果显示，司美格鲁肽组eGFR较基线下降≥50%或因肾脏或心血管原因死亡风险较低（HR=0.76）。肾脏替代治疗的开始时间延迟，但未达到统计学意义（HR=0.84）。因此，司美格鲁肽或可影响2型糖尿病合并慢性肾病患者的临床肾脏终点。GLP-1RA和SGLT-2i的潜在互补证据一项比较GLP-1RA与SGLT-2i疗效的荟萃分析中，纳入5项GLP-1RA相关和3项SGLT-2i相关试验，涉及77242例患者。与安慰剂组相比，GLP-1RA组的心血管不良事件风险降低了12%（HR=0.88），SGLT-2i组的心血管不良事件风险降低了11%（HR=0.89），这表明GLP-1RA和SGLT-2i降低心血管不良事件风险的程度相似。此外，多项荟萃分析结果显示，无论是否患有糖尿病，SGLT2i在射血分数降低的心力衰竭和射血分数保留的心力衰竭中都能将心力衰竭住院降低约30%。GLP-1RA联合SGLT-2i能否进一步降低糖尿病患者的心血管和肾脏事件的发生？理论上来说是可行的，但尚缺乏相关试验来直接验证联合疗法的效果。此前，AMPLITUDE-O试验和Harmony Outcomes试验分别有15.2%（n=618）和6.1%（n=575）的患者在基线时使用SGLT-2i。AMPLITUDE-O试验事后分析发现，基线时SGLT-2i使用者和未使用者的心血管不良事件风险分别降低了30%和26%（HR=0.70和0.74，相互作用P=0.70）、心力衰竭住院风险分别降低了77%和30%（HR=0.23和0.70，相互作用P=0.35）、复合肾脏结局风险分别降低了48%和30%（HR=0.52和0.70，相互作用P=0.38）。Harmony Outcomes试验事后分析未对肾脏结局进行探讨，但也观察到了类似的结果。DECLARE-TIMI 58试验中，4.4%患者基线时使用GLP-1RA，结果显示，SGLT-2i（达格列净）可降低心血管不良事件、心力衰竭住院和复合肾脏结局的风险，这种作用与基线是否使用GLP-1RA无关。从现有研究来看，GLP-1RA和SGLT-2i的作用机制基本上是独立的，但仍需要进一步研究，以评估二者联合治疗是否能够带来更大的临床益处。GLP-1RA+SGLT-2i+非奈利酮的三联治疗策略FIDELIO-DKD、FIGARO-DKD及FIDELITY试验表明，非奈利酮可减少慢性肾病合并糖尿病患者的心血管和肾脏事件发生率，这主要得益于非奈利酮可降低心力衰竭住院风险。这3项大型临床试验的FINE-HEART汇总分析中，非奈利酮降低了心力衰竭住院、白蛋白尿进展复合终点（排除心血管事件影响）、心血管不良事件和全因死亡的风险。参与者中，基线分别有5.8%和8.9%的患者使用GLP-1RA和SGLT-2i，无论这些药物的使用情况如何，非奈利酮对心血管死亡的治疗效果都是一致的。非奈利酮对心血管和肾脏事件的临床益处也不太可能受到GLP-1RA或SGLT-2i联合治疗的影响。但关于非奈利酮联合GLP-1RA和SGLT-2i的附加作用的临床证据仍然有限。有学者将GLP-1RA、SGLT-2i和非奈利酮的相关临床试验数据进行交叉试验分析，以估计三联治疗的效果。研究结果显示，在糖尿病和蛋白尿患者中，相比于常规治疗，三联治疗组的心血管不良事件、心力衰竭住院和慢性肾病进展的风险分别降低了35%（HRs=0.65）、55%（HRs=0.45）和58%（HRs=0.42）。从结果来看，潜在原因是GLP-1RA、SGLT-2i和非甾体MRA的作用机制通常互补和独立、可能部分重叠。因此，这三类药物结合时的效果可能相加。此外，研究还发现，对于50岁以上的患者，相比于单独使用常规疗法，采用三联疗法治疗的患者心血管不良事件、心力衰竭住院和慢性肾病的无事件生存期分别延长了3.2年、3.2年和5.5年。这提示，相比传统疗法或单独用药，GLP-1RA、SGLT-2i和非奈利酮的三联疗法具有更强的心肾保护作用。鉴于现有证据，三联疗法有望提供额外的心脏保护，但需要开展进一步的随机对照试验，以明确三联疗法是否具有相加或协同作用。总结和未来前景联合用药可能进一步增强治疗效果，根据患者情况选择合适药物是未来心血管-肾脏代谢综合征领域的精准治疗方向。2型糖尿病和/或肥胖患者可能受益于联合用药，并改善心血管和肾脏结局。GLP-1RA+SGLT-2i+非奈利酮的方案，可能在心血管和肾脏保护方面具有互补作用。但治疗策略的制定仍需考虑到以下几方面的差异：1）明确从联合治疗中获益的人群；2）明确加强治疗的理想时机和优先级，因为目前的证据不足以弥补这一空白；3）患者接受联合治疗如何维持长期依从性和安全性。本文作者：泰达国际心血管病医院郑刚推荐阅读欢迎投稿：学术成果、前沿进展、临床干货等主题均可，点此了解投稿详情。参考资料（可上下滑动查看）[1] Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol. 2023;20(10):685–95. [2] Vaduganathan M, Mensah GA, Turco JV, et al. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80(25):2361–71. [3] Cea Soriano L, Johansson S, Stefansson B, et al. Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors. Cardiovasc Diabetol. 2015;14:38. [4] de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075–90. [5] American Diabetes Association Professional Practice C: 11. Chronic kidney disease and risk management: standards of care in diabetes-2024. Diabetes Care 2024, 47(Suppl 1):S219-S230. [6] Bornfeldt KE. Does elevated glucose promote atherosclerosis? Pros and Cons Circ Res. 2016;119(2):190–3. [7] Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–93. [8] Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endo crinol. 2017;5(12):951–64. [9] Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a mul tifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91. [10] Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Associa tion (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86. [11] Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474–84. [12] Bjorkegren JLM, Lusis AJ. Atherosclerosis: recent developments. Cell. 2022;185(10):1630–45. [13] Abel ED, Gloyn AL, Evans-Molina C, et al. Diabetes mellitus-progress and opportunities in the evolving epidemic. Cell. 2024;187(15):3789–820. [14] Ritchie RH, Abel ED. Basic mechanisms of diabetic heart disease. Circ Res. 2020;126(11):1501–25. [15] van Raalte DH, Bjornstad P, Cherney DZI, et al. Combination therapy for kidney disease in people with diabetes mellitus. Nat Rev Nephrol. 2024;20(7):433–46. [16] Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. [17] Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular out comes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. [18] Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-con trolled trial. Lancet. 2018;392(10157):1519–29. [19] Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo controlled trial. Lancet. 2019;394(10193):121–30. [20] Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896–907. [21] Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovas cular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463–74. [22] Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20(1):189. [23] Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653–62. [24] Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57. [25] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32. [26] Sawami K, Tanaka A, Node K. Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists. Cardiovasc Diabetol. 2022;21(1):176. [27] Margulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316(5):500–8. [28] Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69–77. [29] Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069–84. [30] Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394–407. [31] Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109–21. [32] Kosiborod MN, Deanfield J, Pratley R, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949–61. [33] Petrie MC, Borlaug BA, Butler J, et al. Semaglutide and NT-proBNP in obesity-related HFpEF. J Am Coll Cardiol. 2024;84(1):27–40. [34] Verma S, Petrie MC, Borlaug BA, et al. Inflammation in obesity-related HFpEF: The STEP-HFpEF Program. J Am Coll Cardiol. 2024;84(17):1646–62.免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。分享，点赞，在看，传递医学新知

临床结果临床成功

2025-04-06

·国际糖尿病idiabetes

IDF 2025先知：聚焦肥胖管理，盘点IDF大会肥胖领域前沿动态！

IDF 2025微专辑扫描二维码可查看更多内容编者按随着全球健康议题关注度攀升，肥胖问题日益凸显，尤其在糖尿病领域，其复杂影响为疾病管理带来巨大挑战。肥胖与糖尿病的交织正重塑全球公共卫生图景。值此国际糖尿病联盟（IDF）成立75周年之际，IDF2025世界糖尿病大会将于4月7日至10日在泰国曼谷隆重召开。大会以"Shape the future of diabetes"为主题，汇聚多学科领域顶尖学者，将聚焦肥胖这一核心议题展开深度研讨与交流。会议内容丰富多元，涵盖多场主旨论坛、专题研讨以及众多优秀壁报展示，将从不同角度、不同层面深入剖析肥胖问题，传递该领域的最新研究动态与前沿成果，为破解肥胖与糖尿病的复杂难题贡献智慧力量。一、讲题环节01糖尿病中的体重管理时间：4月8日16:00-17:00地点：Grand Hall 201讲者：Priya Sumithran、Viral Shah、Anoop Misra话题：涉及2型糖尿病（T2D）中的体重管理策略、GLP-1受体激动剂作为1型糖尿病（T1D）和肥胖症的辅助治疗，以及在低收入环境中如何实施T2D体重管理。02如何解释糖尿病和肥胖症的种族差异时间：4月8日08:30-10:00地点：Amber讲者：Ranjit Mohan Anjana、Ronald Ma、Moffat Nyirenda话题：讨论糖尿病和肥胖症的种族差异是否重要，以及中国、东亚和非洲的相关情况。03肥胖与糖尿病并发症时间：4月8日16:00-17:00地点：Silk 2讲者：Naveed Sattar话题：探讨为什么肥胖是糖尿病并发症的重要因素，而且比想象的更重要?04老年糖尿病的管理时间：4月8日16:35-16:50地点：Silk 1讲者：Kalra Sanjay话题：关注老年人肌肉减少性肥胖和CVD风险05T1D和超重/肥胖时间：4月10日08:30-10:00地点：Nile 1讲者：Catarina Limbert、Paolo Pozzilli、Alok Gupta话题：探讨T1D超重/肥胖的患病率、T1D合并肥胖的新表型与晚期并发症意义，以及治疗T1D超重/肥胖的新方法。06案例研究时间：4月10日15:05-15:20地点：silk 1讲者：Usha Sriram话题：计划怀孕的肥胖伴暴饮暴食症T2D女性案例分享07研发创新时间：4月10日13:50-14:15地点：Silk 1讲者：Juliana Chan话题：种族异质性对T2D及肥胖治疗的影响二、壁报环节（一）一种水杨酸衍生物可改善饮食诱导肥胖小鼠的糖脂代谢并减轻体重A salicylate derivative ameliorates glucose and lipid metabolism with reducing body weight in diet - induced obese mice.时间：4月8日12:15-12:20地点：E - Poster Terminal 1 - Poster Station 1作者：H. Marumo（二）二甲双胍在肥胖儿童和青少年中是否呈现剂量依赖性反应？剂量反应荟萃分析Does metformin show a dose - dependent response in children and adolescents with obesity A dose - response meta - analysis.时间：4月8日12:35-12:40地点：E - Poster Terminal 1 - Poster Station 1作者：I. YADAV（三）饮食模式、时差反应与肥胖、糖尿病和心血管疾病风险：泰国横断面研究结果Eating Patterns, Jetlag, and Risks of Obesity, Diabetes, and CVD: Findings from a Thai Cross - Sectional Study时间：4月8日12:35-12:40地点：E - Poster Terminal 1 - Poster Station 1作者：P. MONGKOLSUCHARITKUL（四）达格列净联合替尔泊肽对体重减轻和血糖调节的综合效应Combined effect of Dapagliflozin and Tirzepatide on Weight loss and Glucose Regulation时间：4月8日13:15-13:20地点：E - Poster Terminal 1 - Poster Station 1作者：J. Abubaker（五）GLP-1/GIP双受体激动剂替尔泊肽联合吡格列酮对大鼠体重减轻和脂质代谢的影响Effects of Dual GLP - 1–GIP Receptor Agonist (Tirzepatide) and Pioglitazone on Weight Loss and Lipid Metabolism in Rats时间：4月8日13:20-13:25地点：E - Poster Terminal 1 - Poster Station 1作者：M. Abu - farha（六）体重减轻对心房颤动消融术后患者代谢参数的影响（HOBIT-FS试验）Effect of weight reduction on metabolic parameters in subjects after atrial fibrillation ablation (HOBIT - FS trial)时间：4月8日12:45-12:50地点：E - Poster Terminal 2 - Poster Station 3作者：L. HORVÁTH（七）助推干预对T2D合并超重成年人饮食和心理健康的12个月影响：一项2x2整群随机对照试验The 12 - month effects of nudging on diet and psychological health in adults with T2DM and overweight: a 2x2 cluster RCT时间：4月8日13:25-13:30地点：E - Poster Terminal 2 - Poster Station 3作者：T. LONG（八）糖尿病患者的肥胖负担——印度青少年起病糖尿病国家登记处（YDR）的结果Burden of Obesity in diabetes patients– Results from the national registry of youth onset diabetes (YDR) in India.时间：4月8日13:15-13:20地点：E - Poster Terminal 3 - Poster Station 1作者：S. SRIVASTAV（九）关于苦味受体多态性作为肥胖遗传标志物的治疗作用的系统评价A systematic review on the therapeutic role of bitter taste receptor polymorphisms as genetic markers in obesity时间：4月8日12:25-12:30地点：E - Poster Terminal 1 - Poster Station 1作者：V. SHIVAM（十）抗性淀粉摄入通过重塑肠道菌群促进人类体重减轻Resistant starch intake facilitates weight loss in humans by reshaping the gut microbiota时间：4月9日15:45-16:00地点：Diabetes Spotlight - Best Posters作者：Wu Qian、Jia Weiping（贾伟平）（十一）新诊断2型糖尿病患者肥胖和睡眠质量的年龄特异性模式Age - Specific Patterns of Obesity and Sleep Quality in Newly Diagnosed Type 2 Diabetes Mellitus时间：4月9日13:10-13:15地点：E - Poster Terminal 1 - Poster Station 3作者：S. PATIL（十二）肥胖中TNF-α/NF-κB介导的Dectin-1上调：连接脂肪组织代谢炎症与糖尿病TNF - α/NF - κB - Mediated Dectin - 1 Upregulation in Obesity: Linking Metabolic Inflammation in Adipose Tissue to Diabetes时间：4月9日13:10-13:15地点：E - Poster Terminal 1 - Poster Station 1作者：A. AL MADHOUN（十三）固定剂量甘精胰岛素联合利西那肽：一种减少T2D低血糖和体重增加的实用选择Fixed - Dose Glargine and Lixisenatide: A Practical Option to Minimize Hypoglycemia and Weight Gain in Type 2 Diabetes时间：4月9日13:20-13:25地点：E - Poster Terminal 1 - Poster Station 2作者：S. Samrat Samajdar（十四）全球1型糖尿病患者超重或肥胖的患病率趋势Trends in the prevalence of overweight or obesity among patients with type 1 diabetes worldwide时间：4月9日12:30-12:35地点：E - Poster Terminal 2 - Poster Station 3作者：Y. Guo、Ji Linong（纪立农）（十五）血清25-羟维生素D水平与糖尿病和肥胖成人全因死亡和心血管死亡率的关系Association of Serum 25 - OH - VitD Levels with All - Cause and Cardiovascular Mortality in Adults with Diabetes and Obesity时间：4 月9日12:45-12:50地点：E - Poster Terminal 2 - Poster Station 1作者：H. Tan, Q. Zeng（四川大学华西医院内分泌与代谢科）（十六）亚洲2型糖尿病超重和肥胖成人中饮食行为的相关因素Factors associated with eating behaviors in overweight and obese adults with type 2 diabetes in Asian population时间：4月9日13:20-13:25地点：E - Poster Terminal 2 - Poster Station 3作者：W. Chee（十七）抗肥胖药物介导的体重减轻和肾脏结局：一个答案背后的多重含义The weight reduction mediated by anti - obesity medication and renal outcome, one answer but with multiple implications时间：4月10日13:25-13:30地点：E - Poster Terminal 2 - Poster Station 3作者：C. Lin（十八）70个低收入和中等收入国家用于体重管理的胰高血糖素样肽-1受体激动剂（GLP-1RA）的适用资格Eligibility for Glucagon - Like Peptide - 1 receptor agonists for weight management in 70 low - and middle - income countries时间：4月10日12:30-12:35地点：E - Poster Terminal 3 - Poster Station 1作者：S.G.K. Yoo（十九）体重变化在生活方式干预对既往有妊娠期糖尿病女性产后2型糖尿病影响中的中介作用Mediating role of weight change in the effect of lifestyle intervention on postpartum T2D in women with previous GDM时间：4月10日13:10-13:15地点：E - Poster Terminal 3 - Poster Station 1作者：G. Hu结语肥胖问题关乎全球健康。IDF2025世界糖尿病大会集结全球顶尖智慧，共探肥胖与糖尿病的病理机制、创新疗法及预防策略，为破解这一全球健康难题贡献智慧力量。会议议程丰富多元，将为参会者带来一场知识与智慧的盛宴。本刊将持续为您带来相关报道，敬请关注！声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《国际糖尿病》编辑部）版权声明版权属《国际糖尿病》所有。欢迎个人转发分享。其他任何媒体、网站未经授权，禁止转载。

临床结果临床研究AHA会议

100 项与胰高血糖素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	胰高血糖素	H04AA01	DB00040

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
糖尿病	加拿大	Eli Lilly Canada, Inc.	2019-09-25
低血糖	美国	Eli Lilly & Co.	1960-11-14

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
1型糖尿病	临床3期	加拿大	Eli Lilly & Co.	2013-09-01
2型糖尿病	临床3期	加拿大	Eli Lilly & Co.	2013-09-01
普通感冒	临床1期	加拿大	Eli Lilly & Co.	2013-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ODP313 (ENDO2022)	N/A	尿崩症 copeptin	-	Glucagon (Healthy Participants)	窪餘獵醖選範顧壓鑰窪(遞齋醖糧範獵膚艱襯鬱) = 獵鹹襯餘築餘廠築網糧構製積願範窪網範獵壓 (窪鏇製淵範遞觸獵鑰積, 2.38 ~ 28.03)	积极	2022-11-01
				Glucagon (Patients with Central Diabetes Insipidus)	窪餘獵醖選範顧壓鑰窪(遞齋醖糧範獵膚艱襯鬱) = 構製糧餘觸觸顧淵廠範構製積願範窪網範獵壓 (窪鏇製淵範遞觸獵鑰積, 0.21 ~ 1.65)
Baqsimi (ESPE2022)	N/A	HbA1c	68	Baqsimi® 3 mg	淵簾製範壓鬱範艱糧壓(餘積齋憲製築壓蓋鹽襯) = 21% 淵憲範蓋觸夢築壓遞衊 (鹽膚廠鑰遞壓顧鏇衊餘 ) 更多	积极	2022-09-15
ADA2022	N/A	-	-	Intraislet Glucagon (GCGRKOβ-cells-/-)	淵艱鬱膚鬱廠選壓製鬱(糧繭獵壓蓋遞網鑰簾願) = 積鏇願簾齋襯窪選選構壓鏇壓糧構鹽蓋鏇築簾 (壓醖製壓鏇鹹齋製鬱淵 )	-	2022-06-01
				Intraislet Glucagon (Littermate controls)	淵艱鬱膚鬱廠選壓製鬱(糧繭獵壓蓋遞網鑰簾願) = 膚窪糧餘蓋築餘餘獵鬱壓鏇壓糧構鹽蓋鏇築簾 (壓醖製壓鏇鹹齋製鬱淵 )
ADA2022	N/A	糖尿病	-	Nasal Glucagon	鏇憲鬱夢構簾糧艱願廠(觸壓獵衊餘醖夢遞遞鹽) = 醖範襯選簾艱範鬱夢醖襯築鏇繭鹽夢簾壓遞鬱 (憲廠餘網齋網網繭醖鏇 )	-	2022-06-01
EASD2021	N/A	低血糖 type 2 diabetes	-	Nasal Glucagon (NG)	遞繭範選蓋廠獵窪顧獵(壓鑰艱衊選襯餘憲積夢) = 壓糧鹽簾築窪網鏇鹹衊遞選廠選糧簾網窪衊夢 (餘鏇繭願襯壓範鑰簾網 ) 更多	积极	2021-09-30
				Liquid Stable Glucagon Rescue Pen (GRP)	遞繭範選蓋廠獵窪顧獵(壓鑰艱衊選襯餘憲積夢) = 選廠製糧膚簾築網鏇衊遞選廠選糧簾網窪衊夢 (餘鏇繭願襯壓範鑰簾網 ) 更多
ADA2021	N/A	低血糖	-	Nasal Glucagon	選範餘鬱蓋蓋齋醖鹹窪(膚製積餘鬱遞鹹蓋鏇憲) = 壓衊積繭網繭廠製膚糧醖願淵憲糧繭糧顧網製 (壓簾鹹齋選獵鏇廠簾襯 )	-	2021-06-01
				Liquid Stable Glucagon Rescue Pen	選範餘鬱蓋蓋齋醖鹹窪(膚製積餘鬱遞鹹蓋鏇憲) = 壓製鹹襯網繭範夢襯製醖願淵憲糧繭糧顧網製 (壓簾鹹齋選獵鏇廠簾襯 )
ADA2021	N/A	低血糖	-	Nasal Glucagon	淵觸廠獵艱廠築積繭簾(襯壓築憲鹹積構製鹹選) = 艱觸齋積積齋鏇鏇襯鏇廠觸餘範構鹹蓋鹹壓糧 (範艱構醖壓膚願襯積願 ) 更多	-	2021-06-01
				Reconstituted Injectable Glucagon	淵觸廠獵艱廠築積繭簾(襯壓築憲鹹積構製鹹選) = 壓顧廠襯遞範壓糧淵鑰廠觸餘範構鹹蓋鹹壓糧 (範艱構醖壓膚願襯積願 ) 更多
NCT03421379 \| NCT03339453 (EASD2020)	N/A	低血糖	-	Nasal glucagon	觸憲簾網構繭構簾淵積(顧鹽遞廠範鹽窪襯窪蓋) = 鬱膚夢鹹願簾窪糧壓蓋範願襯糧製廠獵範壓願 (糧範鬱鑰鬱蓋範築網鬱 ) 更多	积极	2020-09-24
				Injectable glucagon	觸憲簾網構繭構簾淵積(顧鹽遞廠範鹽窪襯窪蓋) = 廠簾獵網鑰繭淵網範構範願襯糧製廠獵範壓願 (糧範鬱鑰鬱蓋範築網鬱 ) 更多
EASD2020	N/A	-	-	Glucagon infusion	淵築壓鑰製遞鏇膚蓋夢(獵鹽遞選襯憲餘膚簾遞) = 網壓範齋遞廠淵糧衊衊積製廠獵製構顧餘鏇窪 (簾襯獵選繭齋鑰夢鏇積 ) 更多	-	2020-09-22
				Control (no glucagon)	淵築壓鑰製遞鏇膚蓋夢(獵鹽遞選襯憲餘膚簾遞) = 廠壓鏇鏇鹽構顧獵膚顧積製廠獵製構顧餘鏇窪 (簾襯獵選繭齋鑰夢鏇積 ) 更多